Importantly, in the context of LSCs, just as in the case of RBM17, EIF4A2 is preferentially expressed in LSC-enriched cell fractions compared to LSC-devoid fractions from AML patients at both mRNA and protein levels (Fig. 6b, c). This evidence concerns the gene EIF4A2 and acute myeloid leukemia.